DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities
RNA molecules have garnered increased attention as potential clinical biomarkers in recent years. While short-read sequencing and quantitative polymerase chain reaction have been the primary methods for quantifying RNA abundance, they typically fail to capture critical post-transcriptional regulatory elements, such as RNA modifications, which are often dysregulated in disease contexts. A promising cutting-edge technique sequencing method that addresses this gap is direct RNA sequencing, offered by Oxford Nanopore Technologies, which can simultaneously capture both RNA abundance and modification information. The rapid advancements in this platform, along with growing evidence of dysregulated RNA species in biofluids, presents a compelling clinical opportunity. In this review, we discuss the challenges and the emerging opportunities for the adoption of nanopore RNA sequencing technologies in the clinic, highlighting their potential to revolutionize personalized medicine and disease monitoring., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership., This project has received funding from the European Union’s Horizon Europe under the grant agreement number 101072892, 101042103, and 101187456 (MSCA-2021-DN, ERC-2021-STG and ERC-2024-POC respectively, to E.M.N.). This work was supported by AECC Foundation (LABE211658NOVO to E.M.N.)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001049-S)., Peer reviewed